Abstract
Little is known about soft tissue sarcomas (STS) in Brazil, once the federal statistics regarding estimates on incidence and mortality of the most common cancers that affect the Brazilian population currently do not include STS. This study aims to perform a broad evaluation and description of the epidemiological profile, access to treatment and main clinical outcomes of the Brazilian STS patient. A population-based cohort study of 66,825 patients who underwent procedures related to STS treatment registered in the Brazilian public health system (Sistema Único de Saúde, SUS) databases. Median age was 57 years, 30% of them older than 65 years and 50.7% of the cohort was female. The majority, 50,383 patients (75.4%), was diagnosed between 2008 and 2015. Most prevalent anatomic sites were upper and lower limbs (12.6%) and the registry of sarcomas without a specific location comprehended 29.7% of the cohort. The majority of patients resided in the Northeast (40.2% of the patients). Surgery was the first treatment modality in 77.7% of the cases. For survival analysis, only patients with stage and histological grade information were included. The 1-, 5- and 10-year survival rate of the patients was, respectively, 75.4% (95% CI = 74.1–76.7%), 43.4% (95% CI = 41.5–45.5%) and 18.6% (95% CI = 14.8–23.3%).
Highlights
Soft-tissue Sarcomas (STS) are a rare and heterogenous group of neoplasms, derived from a myriad of mesodermal cells distributed within the entire body, performing connective roles among over 50 subtypes based on their cell origin and histologic and molecular characteristics, and accounting for less than 1% of all adult solid malignant tumors[1]
The purpose of this study is to perform a broad evaluation and description of the epidemiological profile, access to treatment and main clinical outcomes of the STS patients treated at the Brazilian public health system (Sistema Único de Saúde, SUS)
Data from 66,852 STS patients registered in the Brazilian national databases
Summary
Soft-tissue Sarcomas (STS) are a rare and heterogenous group of neoplasms, derived from a myriad of mesodermal (or mesenchymal) cells distributed within the entire body, performing connective roles among over 50 subtypes based on their cell origin and histologic and molecular characteristics, and accounting for less than 1% of all adult solid malignant tumors[1]. The Brazilian National Cancer Institute (INCA) publishes biannually statistics regarding estimates on incidence and mortality of the most common cancers that affect the Brazilian population, STS not included[2]. Few studies about STS have been published in Brazil so far, most of them covering single institutions experiences, none addressing the consolidated Brazilian scenario. The purpose of this study is to perform a broad evaluation and description of the epidemiological profile, access to treatment and main clinical outcomes of the STS patients treated at the Brazilian public health system (Sistema Único de Saúde, SUS)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
